GSK touts Arexvy sales as it dominates US older adult RSV market, company cuts three early-stage assets

GSK’s RSV vac­cine Arexvy got off to a strong start in its first full quar­ter post-launch, the com­pa­ny re­vealed dur­ing its third-quar­ter earn­ings. It al­so an­nounced it was trim­ming three ear­ly-stage as­sets from its pipeline.

GSK’s to­tal Q3 sales grew by 10% to £8.1 bil­lion ($9.84 bil­lion). Vac­cine per­for­mance as a whole was es­pe­cial­ly ro­bust, with sales to­tal­ing £3.22bn ($3.9 bil­lion). Arexvy made £700 mil­lion ($850 mil­lion) in Q3 and cur­rent­ly ac­counts for two out of every three re­tail pre­scrip­tions for an RSV jab, with the rest made up of ri­val Pfiz­er’s Abrys­vo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.